Bausch + Lomb receives CE Mark approval for new STELLARIS ELITE™ VISION ENHANCEMENT SYSTEM, including the VITESSE® HYPERSONIC VITRECTOMY SYSTEM

Next-Generation Phacoemulsification and Vitreoretinal Platform to Offer Advanced Features and First Major Vitreous Removal Advancement in 40 Years

 

MONTPELLIER, France, Jan.08, 2018 Bausch + Lomb, a leading global eye health company, today announced that it has received CE Mark Approval for the Stellaris Elite™ vision enhancement system, the company’s next generation phacoemulsification and vitreoretinal platform, including Vitesse®, the first and only hypersonic vitrectomy system. The new platform offers many innovations, as well as the opportunity to add upgrades and enhancements continuously, allowing surgeons to customize their systems and expand their capabilities according to their needs.

 

http://bauschsurgical.eu/“The Stellaris Elite platform provides surgeons with a combined system which is responsive, efficient and customisable,” said Luc Bonnefoy, vice president of International Surgical, Bausch + Lomb. “This is yet another example of our company’s continuous commitment to innovating to meet and exceed the surgeons’ evolving needs.”

Stellaris Elite will be the first phacoemulsification platform on the market to offer Adaptive Fluidics™ chamber stabilization system, which combines precise aspiration control with predictive infusion management to create a highly responsive and controlled surgical environment for efficient lens removal.* The new platform also features Attune® energy management system, working synergistically with the chamber stability and vacuum efficiency of Adaptive Fluidics to deliver efficient, low energy controlled emulsification.

 

The Stellaris Elite vision enhancement system will also offer Vitesse, the first and only hypersonic, 100% open port vitrectomy system. The novel Vitesse system, which will be offered exclusively on Stellaris Elite, is the first and only hypersonic, 100% open port vitrectomy platform, representing a revolutionary new approach to vitreous removal. Using patented technology, Vitesse uses highly localized tissue liquification zone at the edge of the port to liquefy vitreous for exceptional control during tissue removal. The open port design is 100% open 100% of the time for continuous flow, and the unique single-lumen design provides completely unobstructed aspiration.

 

The technology for performing vitrectomy has changed little over the last 40 years when the first single port, multi-functional pneumatic cutter was invented. Modern vitrectomy technology today operates at speeds up to 5,000 – 7,500 cuts per minute. With Vitesse the liquefaction rate of vitreous equates to approximately 1.7 million cuts per minute with the objective to decrease the amount of vitreous traction that occurs in vitrectomy.

“After working with Bausch + Lomb in the development of this new technology, from validating the conceptual design to performing the first hypersonic vitrectomies in humans, I believe the new hypersonic vitrector could potentially be the first significant change in the way we remove vitreous since the emergence of guillotine vitrectors in the 70s,” said Paulo Stanga, M.D., a professor of Ophthalmology and Retinal Regeneration at the University of Manchester, and a vitreoretinal surgeon for the Manchester Royal Eye Hospital based in Manchester, United Kingdom. “This new technology represents an important advancement in retinal surgery with the possibility for future and continuous advancements.”

Earlier in April 2017, Bausch + Lomb received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Stellaris Elite vision enhancement system and the Vitesse hypersonic, open port vitrectomy system.

*Data obtained in bench study

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry with products available in more than 100 countries. 

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates. 
© 2018 Bausch & Lomb Incorporated. SUR.PR.EMEA.0118

Contact

Online Beratung - form

Online Beratung - page